

# The interaction of fructose 2,6-bisphosphate with an allosteric site of rat liver fructose 1,6-bisphosphatase

D.W. Meek\* and H.G. Nimmo<sup>+</sup>

*Department of Biochemistry, University of Glasgow, Glasgow G12 8QQ, Scotland*

Received 28 June 1983

Rat liver fructose 1,6-bisphosphatase can be protected against partial inactivation by *N*-ethylmaleimide by low concentrations of fructose 2,6-bisphosphate or high concentrations of fructose 1,6-bisphosphate. The partially inactivated enzyme has a much reduced sensitivity to high substrate inhibition and has lost the sigmoid component of the inhibition by fructose 2,6-bisphosphate; this compound is a simple linear competitive inhibitor of the modified enzyme. The results suggest that fructose 2,6-bisphosphate can bind to the enzyme at two distinct sites, the catalytic site and an allosteric site. High levels of fructose 1,6-bisphosphate probably inhibit by binding to the allosteric site.

<i>Fructose 1,6-bisphosphatase</i>	<i>Fructose 2,6-bisphosphate</i>	<i>N-Ethylmaleimide</i>
<i>High substrate inhibition</i>	<i>Allosteric site</i>	

## 1. INTRODUCTION

Fructose 2,6-bisphosphate (F2,6P<sub>2</sub>) is thought to play a key role in the regulation of carbohydrate metabolism in liver [1]. Its level in liver varies in response to hormones and to changes in dietary status. It is an activator of phosphofructokinase and an inhibitor of fructose 1,6-bisphosphatase (F1,6P<sub>2</sub>ase) and its level could therefore control glycolysis and gluconeogenesis at the level of the fructose 6-phosphate-fructose 1,6-bisphosphate (F1,6P<sub>2</sub>) cycle [1].

There has been considerable controversy regarding the mechanism of the inhibition of liver F1,6P<sub>2</sub>ases by F2,6P<sub>2</sub>. In [2] it was reported that F2,6P<sub>2</sub> was a simple competitive inhibitor of rat liver F1,6P<sub>2</sub>ase with respect to F1,6P<sub>2</sub> and they concluded that F2,6P<sub>2</sub> interacted with the enzyme at the catalytic site. Similar conclusions have been drawn from kinetic and chemical modification data for the F1,6P<sub>2</sub>ases from rabbit and pig liver

[3,4]. However, authors in [5] argued that the inhibition of rat liver F1,6P<sub>2</sub>ase by F2,6P<sub>2</sub> was more complex than this. They showed that in kinetic experiments F2,6P<sub>2</sub> reduced the affinity of the enzyme for F1,6P<sub>2</sub> and also induced co-operativity in the response to F1,6P<sub>2</sub>. There is also general agreement that the inhibitions of liver F1,6P<sub>2</sub>ases by AMP and F2,6P<sub>2</sub> are synergistic [2-6]. Moreover, F2,6P<sub>2</sub> but not F1,6P<sub>2</sub> can protect the AMP-binding properties of rat liver F1,6P<sub>2</sub>ase against modification by acetylimidazole [6]. These 3 findings are consistent with the idea that F2,6P<sub>2</sub> interacts with an allosteric site on F1,6P<sub>2</sub>ase distinct from both the catalytic site and the AMP site.

We report here observations that suggest that F2,6P<sub>2</sub> can interact with two distinct sites on rat liver F1,6P<sub>2</sub>ase and we propose that high substrate inhibition of liver F1,6P<sub>2</sub>ases results from binding of F1,6P<sub>2</sub> to the allosteric site for F2,6P<sub>2</sub>.

## 2. MATERIALS AND METHODS

Glucose 6-phosphate dehydrogenase, phosphoglucose isomerase, NADP<sup>+</sup>, F1,6P<sub>2</sub> and

\* Present address: Department of Molecular Biology, University of Edinburgh, Scotland

<sup>+</sup> To whom correspondence should be addressed

triethanolamine hydrochloride were obtained from Boehringer (London). *N*-Ethylmaleimide (NEM) was obtained from Aldrich (Gillingham). 5,5'-Dithio-bis-(2-nitrobenzoate) (Nbs<sub>2</sub>) was obtained from Sigma (London). F<sub>2</sub>,6P<sub>2</sub> was prepared using a minor modification of the method in [7]; during the hydrolysis of F<sub>1</sub>,6P<sub>2</sub> by F<sub>1</sub>,6P<sub>2</sub>ase, 10 mM MgCl<sub>2</sub> was used instead of 0.5 mM MnCl<sub>2</sub>. All other chemicals were of the highest available purity.

F<sub>1</sub>,6P<sub>2</sub>ase was purified to homogeneity from rat liver by a method involving fractionation with (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> and chromatography on DEAE-cellulose, Procion red-Sepharose and Sephadex G200 [8]. The purified enzyme was free from proteolytic degradation as judged by its subunit molecular mass, its sensitivity to AMP and its pH-activity profile [8]. For treatment with *N*-ethylmaleimide the enzyme (0.125 mg/ml) was incubated in 50 mM triethanolamine hydrochloride-KOH (pH 7.5) containing 100 mM KCl and the additions indicated in the text at 0°C. At zero time NEM was added to a final concentration of 25 μM. Samples were removed at various times and assayed for F<sub>1</sub>,6P<sub>2</sub>ase using the standard assay.


F<sub>1</sub>,6P<sub>2</sub>ase was assayed by coupling the production of fructose 6-phosphate to the reduction of NADP<sup>+</sup>. The standard assay conditions were those given in [9]. For kinetic experiments (fig.2,3) a slightly modified method was used; each cuvette contained, in 2 ml, 50 mM triethanolamine hydrochloride-KOH (pH 7.2), 100 mM KCl, 10 μM EDTA, 0.15 mM NADP<sup>+</sup>, 5 units of phosphoglucose isomerase and 3 units of glucose 6-phosphate dehydrogenase. The concentrations of free Mg<sup>2+</sup>, F<sub>1</sub>,6P<sub>2</sub> and F<sub>2</sub>,6P<sub>2</sub> were as stated in the text. The reaction was initiated by the addition of F<sub>1</sub>,6P<sub>2</sub>ase and the reduction of NADP<sup>+</sup> was monitored at 25°C using a Hitachi Perkin-Elmer MPF 2A spectrofluorimeter. The excitation and emission wavelengths were 340 nm and 460 nm, respectively, and the instrument was adjusted to give a full scale deflection corresponding to 0.5 μM NADPH. The association constant for the Mg<sup>2+</sup>-F<sub>1</sub>,6P<sub>2</sub> complex was taken to be 250 M<sup>-1</sup> [10] and that for the Mg<sup>2+</sup>-F<sub>2</sub>,6P<sub>2</sub> complex was found to be 350 M<sup>-1</sup> using the method in [11]. Kinetic plots were analysed using a weighted least mean squares linear regression method [12].

### 3. RESULTS AND DISCUSSION

Liver F<sub>1</sub>,6P<sub>2</sub>ases are inhibited by high levels of F<sub>1</sub>,6P<sub>2</sub> (e.g., [10,13]). Treatment of an ox liver F<sub>1</sub>,6P<sub>2</sub>ase with *p*-chloromercuribenzoate abolished the sensitivity of the enzyme to this high substrate inhibition but did not greatly affect its catalytic properties or its allosteric response to AMP [10]. Moreover, inhibitory levels of F<sub>1</sub>,6P<sub>2</sub>, but not non-inhibitory levels, protected the enzyme against thiol group reagents [10]. These observations suggest that the inhibition of liver F<sub>1</sub>,6P<sub>2</sub>ases by high levels of F<sub>1</sub>,6P<sub>2</sub> may be mediated by low affinity binding of F<sub>1</sub>,6P<sub>2</sub> to a site distinct from the catalytic site; this site could be an allosteric F<sub>2</sub>,6P<sub>2</sub> site.

Titration of the thiol groups of rat liver F<sub>1</sub>,6P<sub>2</sub>ase with a large excess of Nbs<sub>2</sub> revealed the presence in the native enzyme of 0.8 rapidly reacting thiol groups per subunit (not shown). Titrations carried out in the presence of 8 M urea showed the presence of 7.0 thiol groups per subunit; this is consistent with the cysteine content determined by amino acid analysis [8]. The rapid reaction of native F<sub>1</sub>,6P<sub>2</sub>ase with Nbs<sub>2</sub> correlated with a 50% decrease in the activity of the enzyme. However, the activity of the enzyme continued to decline slowly even after the reaction with Nbs<sub>2</sub> had been terminated by the addition of excess dithiothreitol and so the kinetic properties of Nbs<sub>2</sub>-modified F<sub>1</sub>,6P<sub>2</sub>ase were not examined. These results show that rat liver F<sub>1</sub>,6P<sub>2</sub>ase resembles other F<sub>1</sub>,6P<sub>2</sub>ases in containing one particularly reactive thiol group per subunit.

The results in fig.1 show that the addition of NEM to rat liver F<sub>1</sub>,6P<sub>2</sub>ase causes 50–55% inactivation of the enzyme in a reaction that is complete after about 20 min; no further decrease in activity took place over 1 h. F<sub>2</sub>,6P<sub>2</sub> (100 μM) afforded complete protection against inactivation, and F<sub>1</sub>,6P<sub>2</sub> (5 mM) gave significant, though not complete, protection (fig.1). The results from a series of protection experiments are summarised in table 1. While 4 μM F<sub>2</sub>,6P<sub>2</sub> gave considerable protection and 10 μM F<sub>2</sub>,6P<sub>2</sub> gave complete protection, 200 μM F<sub>1</sub>,6P<sub>2</sub> gave no protection; this concentration is about 100-times the *K<sub>m</sub>* of the enzyme for F<sub>1</sub>,6P<sub>2</sub> [14]. These results show that the target for modification by NEM is a high affinity binding site for F<sub>2</sub>,6P<sub>2</sub> and a low affinity binding site for




**Fig. 1.** The effect of NEM on the activity of rat liver F1,6P<sub>2</sub>ase. F1,6P<sub>2</sub>ase was incubated as described in section 2. The standard assay for F1,6P<sub>2</sub>ase was used. Symbols represent: no NEM (●), NEM with no other additions (○), NEM plus 5 mM F1,6P<sub>2</sub> (Δ), NEM plus 100 μM F2,6P<sub>2</sub> (▲).

Table 1

The protection of rat liver F1,6P<sub>2</sub>ase against inactivation by NEM

Addition	Activity remaining (%)
None	55
0.2 mM F1,6P <sub>2</sub>	58
5 mM F1,6P <sub>2</sub>	94
0.2 mM AMP	50
0.2 mM AMP + 0.2 mM F1,6P <sub>2</sub>	54
5 mM Fructose 6-phosphate	65
5 mM P <sub>i</sub>	61
4 μM F2,6P <sub>2</sub>	87
10 μM F2,6P <sub>2</sub>	98
100 μM F2,6P <sub>2</sub>	102

F1,6P<sub>2</sub>ase was incubated with NEM for 20 min as in section 2 with the indicated additions. Activity is expressed as a percentage of the value at zero time. No activity was lost in the absence of NEM




**Fig. 2.** Dixon plots for the inhibition of control and NEM-treated F1,6P<sub>2</sub>ase by high levels of F1,6P<sub>2</sub>. Control F1,6P<sub>2</sub>ase (○), F1,6P<sub>2</sub>ase modified with NEM as described in the text (□). The fluorimetric assay was used and the free Mg<sup>2+</sup> concentration was 2 mM.

F1,6P<sub>2</sub>; it is not the catalytic site. Neither AMP, in the presence or absence of F1,6P<sub>2</sub>, nor fructose 6-phosphate nor P<sub>i</sub> afforded any significant protection against NEM.

A sample of rat liver F1,6P<sub>2</sub>ase was treated with NEM in the absence of any protecting agents. The reaction was terminated by the addition of excess dithiothreitol after 30 min; the enzyme activity remained constant after this treatment. The inhibition of control and NEM-treated F1,6P<sub>2</sub>ases by F1,6P<sub>2</sub> and F2,6P<sub>2</sub> was then examined. Fig. 2 shows Dixon plots for the inhibition by high levels of F1,6P<sub>2</sub>. The values of K<sub>i</sub> for F1,6P<sub>2</sub> were 150 μM and 850 μM for the control and NEM-treated samples, respectively. This shows that the reaction of F1,6P<sub>2</sub>ase with NEM caused a very considerable reduction in the affinity of the enzyme for F1,6P<sub>2</sub> as an inhibitor.

The inhibition by F2,6P<sub>2</sub> is expressed in fig. 3 as double reciprocal plots of velocity against F1,6P<sub>2</sub> concentration at different levels of F2,6P<sub>2</sub>. For the control F1,6P<sub>2</sub>ase F2,6P<sub>2</sub> clearly induces co-operativity in the response to F1,6P<sub>2</sub> (fig. 3a); the response to F2,6P<sub>2</sub> is itself co-operative [14]. These



results agree with those in [5]. For the NEM-treated enzyme F2,6P<sub>2</sub> is a linear competitive inhibitor with respect to F1,6P<sub>2</sub> and the enzyme responds hyperbolically to F1,6P<sub>2</sub> (fig.3b). Slope replots of the data in fig.3b are linear (not shown), indicating that the NEM-treated enzyme does not respond co-operatively to F2,6P<sub>2</sub>. The  $K_m$  of the NEM-treated enzyme for F1,6P<sub>2</sub> is 1.4  $\mu\text{M}$  at 2.0 mM free  $\text{Mg}^{2+}$  ions (fig.3b); this is similar to the value for the control enzyme [14].

The simplest interpretation of these data involves the assumptions that F2,6P<sub>2</sub> can interact at two sites on F1,6P<sub>2</sub>ase, the catalytic site and an allosteric site, and that high substrate inhibition is caused by low affinity binding of F1,6P<sub>2</sub> to the allosteric site. We assume that NEM reacts preferentially with the one particularly reactive thiol group per subunit; the protection data suggest that this group is adjacent to or part of the allosteric site. The reaction of this thiol group with NEM seems to prevent binding of F2,6P<sub>2</sub> to the allosteric site completely and to reduce the affinity of this site for F1,6P<sub>2</sub> considerably.

These ideas are compatible with much previous work on F1,6P<sub>2</sub>ases and go some way towards resolving the controversy concerning the mechanism of action of F2,6P<sub>2</sub>. The interaction of F2,6P<sub>2</sub> with an allosteric site is supported by a number of observations. The effects of F2,6P<sub>2</sub> and AMP are synergistic [2-6,14], F2,6P<sub>2</sub> induces cooperativity in the response to F1,6P<sub>2</sub> [5,6,14] and F2,6P<sub>2</sub> gives sigmoid inhibition of F1,6P<sub>2</sub>ase [5,14]. None of these effects would be expected of a simple competitive inhibitor. Moreover, F2,6P<sub>2</sub> can protect the AMP site of rat liver F1,6P<sub>2</sub>ase against modification by acetylimidazole [6] and can protect the rabbit liver enzyme against proteolysis [3] whereas levels of F1,6P<sub>2</sub> sufficient to saturate the catalytic site but not to cause high substrate inhibition do not have these effects. Our observation that NEM both reduces the  $K_i$  for

Fig.3. Inhibition of F1,6P<sub>2</sub>ase by F2,6P<sub>2</sub>. The fluorimetric assay was used and the free  $\text{Mg}^{2+}$  concentration was 2 mM. (a) Control F1,6P<sub>2</sub>ase. The F2,6P<sub>2</sub> concentrations were 0 (●), 1.5  $\mu\text{M}$  (△), 2.9  $\mu\text{M}$  (▲), 5.9  $\mu\text{M}$  (□) and 11.8  $\mu\text{M}$  (■); (b) F1,6P<sub>2</sub>ase modified with NEM as described in the text. The F2,6P<sub>2</sub> concentrations were 0 (○), 1.2  $\mu\text{M}$  (●), 2.4  $\mu\text{M}$  (△) and 3.5  $\mu\text{M}$  (▲).

F1,6P<sub>2</sub> as an inhibitor and eliminates the sigmoid component of the inhibition by F2,6P<sub>2</sub> strongly suggests that the allosteric site for F2,6P<sub>2</sub> can also bind F1,6P<sub>2</sub> with low affinity and that this is responsible for the high substrate inhibition of the enzyme. In agreement with this, high levels of F1,6P<sub>2</sub> cause little or no additional inhibition if F2,6P<sub>2</sub> is present [5,14]. The fact that F2,6P<sub>2</sub> is a simple linear competitive inhibitor of NEM-treated F1,6P<sub>2</sub>ase with respect to F1,6P<sub>2</sub> indicates that F2,6P<sub>2</sub> can also bind to the catalytic site of the enzyme. This is supported by the observations that F2,6P<sub>2</sub> can protect the enzyme against inactivation by acetylimidazole [4,6] and pyridoxal phosphate [3].

Our suggestion that F2,6P<sub>2</sub> can interact with F1,6P<sub>2</sub>ase at two distinct sites could be tested directly by binding studies. However, our model for the allosteric properties of rat liver F1,6P<sub>2</sub>ase [14] indicates that binding of more than one molecule of F2,6P<sub>2</sub> per subunit might be detectable only at high concentrations of F2,6P<sub>2</sub>. Ultimately, crystallographic studies may be required to resolve this problem.

#### ACKNOWLEDGEMENT

D.W.M. was the recipient of a Research Studentship from the Medical Research Council, U.K.

#### REFERENCES

- [1] Van Schaftingen, E. and Hers, H.G. (1982) *Biochem. J.* 206, 1–12.
- [2] Pilkis, S.J., El-Maghrabi, M.R., Pilkis, J. and Claus, T.H. (1981) *J. Biol. Chem.* 256, 3619–3622.
- [3] Pontremoli, S., Melloni, E., Michetti, M., Salamino, F., Sparatore, B. and Horecker, B.L. (1982) *Arch. Biochem. Biophys.* 218, 609–613.
- [4] Gottschalk, M.E., Chatterjee, T., Edelstein, I. and Marcus, F. (1982) *J. Biol. Chem.* 257, 8016–8020.
- [5] Van Schaftingen, E. and Hers, H.G. (1981) *Proc. Natl. Acad. Sci. USA* 78, 2861–2863.
- [6] Pilkis, S.J., El-Maghrabi, M.R., McGrane, M.M., Pilkis, J. and Claus, T.H. (1981) *J. Biol. Chem.* 256, 11489–11495.
- [7] Van Schaftingen, E. and Hers, H.G. (1981) *Eur. J. Biochem.* 117, 319–323.
- [8] Meek, D.W. and Nimmo, H.G. (1983) in preparation.
- [9] Nimmo, H.G. and Tipton, K.F. (1975) *Biochem. J.* 145, 323–334.
- [10] Nimmo, H.G. and Tipton, K.F. (1975) *Eur. J. Biochem.* 58, 567–574.
- [11] Burton, K. (1959) *Biochem. J.* 71, 388–395.
- [12] Roberts, D.V. (1977) *Enzyme Kinetics*, Cambridge University Press, London.
- [13] Taketa, K. and Pogell, B.M. (1965) *J. Biol. Chem.* 240, 651–662.
- [14] Meek, D.W. and Nimmo, H.G. (1983) in preparation.